Warning letter
Lonza Walkersville, Inc.: warning letter of Apr 21, 2017
FDA warning letter 520239 · Baltimore District Office
Key facts
| Reference number | 520239 |
|---|---|
| Company | Lonza Walkersville, Inc. |
| Subject | CGMP/QSR/Medical Devices/Adulterated |
| Issue date | Apr 21, 2017 |
| Posted date | May 9, 2017 |
| Issuing office | Baltimore District Office |
| Product type | Devices |
| CFR sections cited | 820 |
| Inspection city | Walkersville |
| Inspection ZIP | 21793 |
| Inspection start date | Jan 18, 2017 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: